Joshua Urrutia
5PUBLICATIONS
21CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jun 19, 2021
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.Dae-Hwan Kim, Duanchen Sun, William K Storck
|Jul 31, 2020
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.Xiangnan Guan, Duanchen Sun, Eric Lu
|May 20, 2020
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.Joshi J Alumkal, Duanchen Sun, Eric Lu
|Apr 19, 2019
BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer.Daniel J Coleman, Lina Gao, Carly J King
Pageof 1
Frequent Collaborators
5 joint publications
Zheng Xia
4 joint publications
Joshi J Alumkal
2 joint publications
Matthew Rettig
2 joint publications
Tomasz M Beer
2 joint publications
Jack Youngren
2 joint publications
Alana S Weinstein
2 joint publications
Jacob Schwartzman
1 joint publications
Dae-Hwan Kim
1 joint publications
Anbarasu Kumaraswamy
1 joint publications
Mark P Labrecque
